Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer’s study, with a new target in their sights

W ith the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, a startup out of San Francisco has identified a brand new target and now has a $76 million B round to put it through its first proof-of-concept study.